Clinical Trial Update: Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing docetaxel plus dasatinib vs docetaxel plus placebo in castration-resistant prostate cancer; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DASATINIB (Dasatinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2014-02-06